| scholarly article | Q13442814 |
| P50 | author | Deyan Y Yosifov | Q39066107 |
| Stephan Stilgenbauer | Q47158807 | ||
| Daniel Mertens | Q50861917 | ||
| P2093 | author name string | Peter Lichter | |
| Hartmut Döhner | |||
| Johannes Bloehdorn | |||
| P2860 | cites work | An integrated encyclopedia of DNA elements in the human genome | Q22122150 |
| Replication in Genome-Wide Association Studies | Q24288830 | ||
| TP53 mutation and survival in chronic lymphocytic leukemia | Q27851577 | ||
| Genomic aberrations and survival in chronic lymphocytic leukemia | Q28141442 | ||
| Mapping and analysis of chromatin state dynamics in nine human cell types | Q29547552 | ||
| A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data | Q30578296 | ||
| Non-specific filtering of beta-distributed data | Q30832120 | ||
| Comprehensive analysis of DNA methylation data with RnBeads | Q30855530 | ||
| Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group | Q33402713 | ||
| Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia | Q33898309 | ||
| Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia | Q34052080 | ||
| Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial | Q34141305 | ||
| Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia | Q34402999 | ||
| Genome-wide methylation and expression differences in HPV(+) and HPV(-) squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis | Q35124426 | ||
| Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification | Q36022313 | ||
| Low-level processing of Illumina Infinium DNA Methylation BeadArrays | Q36769462 | ||
| Additional annotation enhances potential for biologically-relevant analysis of the Illumina Infinium HumanMethylation450 BeadChip array | Q37088466 | ||
| From pathogenesis to treatment of chronic lymphocytic leukaemia | Q37643423 | ||
| Chronic lymphocytic leukemia (CLL)-Then and now. | Q38675358 | ||
| Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia | Q38787719 | ||
| Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial | Q39005118 | ||
| Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels | Q39025763 | ||
| First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority tri | Q40662825 | ||
| Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation | Q42208521 | ||
| Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage | Q43256441 | ||
| Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. | Q45915574 | ||
| Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia. | Q48326934 | ||
| Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. | Q50932977 | ||
| The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia | Q57090272 | ||
| Evaluation of the Infinium Methylation 450K technology | Q82726350 | ||
| Economic Impact of Oral Therapies for Chronic Lymphocytic Leukemia-the Burden of Novelty | Q89459131 | ||
| From Biology to Therapy: The CLL Success Story | Q91274177 | ||
| Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia | Q92314359 | ||
| P4510 | describes a project that uses | limma | Q112236343 |
| P433 | issue | 1 | |
| P921 | main subject | chronic lymphocytic leukemia | Q1088156 |
| P304 | page(s) | 133 | |
| P577 | publication date | 2020-05-01 | |
| P1433 | published in | Scientific Data | Q27725928 |
| P1476 | title | DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy | |
| P478 | volume | 7 |
Search more.